ArticleOncology reports2026
SRRT promotes prostate cancer progression and serves as a prognostic biomarker through STAT3 pathway activation.
Article in Oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PC) is a highly prevalent malignancy in men with substantial prognostic heterogeneity. The present study aimed to identify novel prognostic biomarkers and investigate their functional roles and underlying mechanisms in PC. To this end, integrated bioinformatics analyses were performed using The Cancer Genome Atlas‑prostate adenocarcinoma cohort and two Gene Expression Omnibus datasets. A total of 95 common differentially expressed genes were identified and were significantly enriched in the STAT3 signaling pathway. Lasso and Cox regression analyses screened nine independent prognostic genes, among which SRRT exhibited the highest risk coefficient. The constructed risk model showed strong predictive performance for disease‑free survival and favorable calibration in nomogram analysis. Experimental validation demonstrated that SRRT was markedly upregulated in PC tissues and cell lines, and functional assays revealed that SRRT knockdown inhibited, whereas overexpression promoted, proliferation and migration of DU145 and PC‑3 cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.